Ira Winer, MD, PhD, Talks Best Data to Come Out of SGO 2022


Ira Winer, MD, PhD, FACOG, spoke about which presentations during The Society of Gynecologic Oncology 2022 Annual Meeting he most enjoyed.

During The Society of Gynecologic Oncology (SGO) 2022 Annual Meeting on Women’s Cancer, CancerNetwork® spoke with Ira Winer, MD, PhD, FACOG, a gynecologic oncologist at the Karmanos Cancer Center and associate professor in the Division of Gynecologic Oncology at Wayne State University in Detroit, about the future of ovarian cancer treatment and ongoing trials that were presented at the conference that he’s eager to see results of.


The most interesting thing about SGO this year was the trajectory [showing] how much we’re moving towards targeted therapies and individualized therapies, even in the IO [immuno-oncology] realm, as well as the non-IO realm. If you listen, especially to some of the plenaries, you could hear that we’re really digging into the mechanistic complex of how these [tumors] work in terms of how their disease responds to these treatments. [Given that], we’ll be able to better target the cancers in the future, but also choose the right patients for the right treatment. That is the most exciting. Over the course of SGO, [presentations continually proved] how things are moving in that direction. Even in the IO realm, we had some secondary analyses of various trials to look at why perhaps patients responded versus didn’t respond. That’s going to allow us to better design our trials in the future, and also hopefully to better sequence treatments, whether it’s IO or not. That was the most exciting thing about this SGO.

Related Videos
Considering cystectomy in patients with bladder cancer may help with managing the shortage of Bacillus Calmette-Guerin, according to Joshua J. Meeks, MD, PhD, BS.
Anemia in patients who receive talazoparib plus enzalutamide for metastatic castration-resistant prostate cancer appears to be manageable without any compromises in patient-reported outcomes and quality of life.
Patients with locally advanced or metastatic urothelial cancer and visceral disease may particularly benefit from enfortumab vedotin plus pembrolizumab, according to Amanda Nizam, MD.
High-grade adverse effects with zanidatamab plus palbociclib and fulvestrant seem to be uncommon in patients with HER2-positive, hormone receptor–positive, metastatic breast cancer, according to Sara Hurvitz, MD, FACP.
Black male patients with breast cancer appear to experience worse survival outcomes compared with White patients when controlling for clinicopathological variables, according to Jason (Jincong) Q. Freeman, MPH, MS.
Results from the ECOG-ACRIN E4112 trial appear to support the use of DCIS scores for identifying patients with breast cancer who may be eligible to omit radiotherapy following MRI-guided surgery.
Providers should inform patients with breast cancer that selecting later-line therapies following prior treatment with CDK4/6 inhibitors is a “developing area,” says Abigail M. Johnston, JD.
Data from the phase 3 NATALEE trial highlight a positive toxicity profile for ribociclib as an adjuvant therapy for patients with hormone receptor–positive, HER2-negative breast cancer, says Neil M. Iyengar, MD.
Future research will focus on ctDNA dynamics change over time in the full translational cohort of patients with hormone receptor–positive breast cancer in the phase 3 monarchE study, says Stephanie L. Graff, MD.
Findings from a National Cancer Database analysis highlight no statistically significant differences in survival outcomes with chemotherapy for patients over 81 years old with triple-negative breast cancer compared with those who do not receive chemotherapy.
Related Content